Navigation Links
FDA Announces Safety Risk Associated with HIV Drug
Date:2/1/2010

Rare, but serious, liver disorder reported in some patients

SILVER SPRING, Md., Feb. 1 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that non-cirrhotic portal hypertension, a rare, but serious, liver disorder, has been reported in some HIV patients taking Videx/Videx EC (didanosine).

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO )

Videx is an antiretroviral medicine first approved by the FDA in 1991. Videx EC is a delayed-release version of Videx approved in 2000. Videx/Videx EC is used in combination with other antiretroviral medicines to treat HIV infection in children and adults.

During an 18-year period, 42 cases of non-cirrhotic portal hypertension were reported to the FDA's Adverse Event Reporting System for patients taking Videx/Videx EC. Four patients died from bleeding or liver failure after developing the condition.

Non-cirrhotic portal hypertension occurs when blood flow in the portal vein -- a major vein in the liver -- slows down and leads to severely enlarged veins in the esophagus. These enlarged veins, called esophageal varices, are thin and can break open, resulting in serious, and potentially fatal, bleeding.

The Videx and Videx EC product labels have been revised to help ensure that health care professionals and patients are aware of the risk and the signs and symptoms of non-cirrhotic portal hypertension.

The FDA evaluation concluded that the clinical benefits of Videx/Videx EC in certain patients with HIV continue to outweigh potential safety risks. Videx/Videx EC does not cure HIV infection, may not prevent development of HIV-related illnesses, and may not prevent the spread of HIV to other people.  

Videx/Videx EC is marketed by Princeton, N.J.-based Bristol-Myers Squibb.

For more information:

FDA Drug Safety Communication: Serious liver disorder associated with the use of Videx/Videx EC (didanosine)

http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm199169.htm  

Media Inquiries: Erica Jefferson, 301-796-4988; erica.jefferson@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

RELATED LINKS
http://www.fda.gov/

'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Recondo Technology Announces Omni278 UnitedHealthcare Admission Notification Service
2. Trek Bicycle Announces Title Sponsorship of 2010 Dirt Series
3. Sinovac Announces Exercise of Over-Allotment Option
4. Rapport International Announces Partnership with SDL
5. DBLG Announces Release 1.0 of the HITECH Act Survival Guide: an Open Source Law Initiative
6. Southwest Airlines Announces Recipients of its 2010 Medical Transportation Grant Program
7. Dr. David Williams Announces Launch of New Online Digestion Clinic
8. Code Hennessy & Simmons LLC Announces Sale of Suture Express, Inc.
9. Care Investment Trust Inc. Announces Stockholder Approval of Plan of Liquidation
10. PDL BioPharma Announces Two $0.50 Dividends in 2010
11. AMD Alliance International Announces $10,000 Video Contest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ... is growing as it continues developing an ANSI-approved, consensus-based American National Standard ... which plans to publish the first ANSI-approved GMP standard for dietary supplements ...
(Date:3/29/2017)... , ... March 29, 2017 , ... HealthCareMandA.com will host ... April 20, 2017, at 1:00 PM ET. A recording of the webinar will also ... Webinar Series. , Home health and hospice companies are still popular targets for healthcare ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... of Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who ... at Intercontinental Time Square, New York. , The program will be led ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... Tuesday, ... asking the American public to take the Diabetes Risk Test to find out if ... the Los Angeles World Airports will light up the evening sky by programming the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution for Truth has organized ... protect parental rights and civil liberties, and to restore transparency within government agencies ... coincides with a press conference taking place Friday morning calling on President Trump ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ - Medicure Inc. ("Medicure") ... financial results for the year ended December 31, ... 2017. The results are being released later than ... statements will include the operations and balances of ... 2016.  This release and filing date meets TSX ...
(Date:3/28/2017)... "Chemotherapy Induced Neutropenia (CIN) – Market Insights, Epidemiology and ... market trends of the Chemotherapy Induced Neutropenia for the seven major ... ( France , Germany ... UK) and Japan , as well as rest ... world (RoW). The Report covers the therapeutics market revenue, ...
(Date:3/28/2017)... , March 28, 2017  "US Cancer ... on the various indicators and trend analysis related ... drugs in mainstream pharmaceutical market in US. The ... for the growth on cancer generics drugs in ... in saving of billions of dollars for various ...
Breaking Medicine Technology: